9 November 2026 · Updated November 2026 · 11 min read

Exosomes After Microneedling: Sequencing, Contact Time and Aftercare

Exosomes after microneedling: where the step sits in published protocols, how long channels stay open, aftercare, and what an authorized device covers.

ExosomesMicroneedlingAftercareChannel ClosureSplit-Face TrialsLot DocumentationFDA Regulation
BB
Cited sources

In the published studies of exosomes after microneedling, the exosome material goes onto the skin once the needle pass is complete, while the channels the needles opened are still fresh [1, 2, 3, 4]. Human measurements show those channels beginning to reseal within hours [7], which is why the timing of the exosome step deserves a place in every session record.

This guide sets out where the exosome step sits in the published protocols, how long microneedle channels stay open, what aftercare the study protocols and the FDA describe, what an FDA-authorized microneedling device covers, and what a practice can document for each lot. It is written for practitioners and is readable by patients preparing for an appointment.

2 h
for unoccluded microneedle sites to recover barrier properties in human volunteers, measured in 2011 (Gupta 2011)
12 to 18 h
for dye-marked microneedle pores to close in a 2011 animal model, by needle length (Kalluri 2011)
21
sources cited and annotated, including 4 FDA records, all from 2011 or later

Regulatory position

The FDA stated in its 2019 public safety notification that there are currently no FDA-approved exosome products, and the notification remains posted on fda.gov as of 9 November 2026 [15]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats. The federal identification for aesthetic microneedling devices at 21 CFR 878.4430 excludes devices intended for transdermal delivery of topical products [13], and the FDA states that microneedling devices are not approved for delivering topical products into the skin [12]. Sequencing, contact time, aftercare and patient selection are practitioner decisions this guide does not make.

Sequencing in the published protocols places the exosome step after the needle pass

Four controlled studies describe the order of steps in a microneedling session with vesicle or secretome material. Estupiñan, Ly and Goldberg reported in 2025 that topical exosomes and PRP were applied immediately after each RF microneedling session, one material to each half of the face, across three sessions four weeks apart [2]. Yen and colleagues reported in 2026 an unblinded, randomized split-face study of 60 adults in which one side received RF microneedling followed by a topical extracellular vesicle preparation and the other RF microneedling alone [4].

Yusharyahya and colleagues described in 2023 microneedling to a depth of 150 micrometers until diffuse erythema appeared, followed by a topical secretome application, and compared that route with fractional CO2 laser in 30 women [3]. Park GH and colleagues reported in 2023 that an exosome-containing solution was applied with microneedling on one side of the face and saline on the other across three sessions three weeks apart [1].

StudyDeviceWhen the material was appliedAftercare the record describesn
Park GH 2023 [1]Mechanical microneedlingWith microneedling at each of three sessions; saline on the control sideFollow-up six weeks after the last session; aftercare not described in the abstract28
Estupiñan 2025 [2]RF microneedlingImmediately after the device sessionActive skin care stopped for the study; exosome cream on one side and petroleum jelly on the other for 10 days15
Yusharyahya 2023 [3]Mechanical microneedling at 150 micrometers, or fractional CO2After needling to diffuse erythemaCleanser paused 4 hours, sunscreen 1 day and retinoic acid cream 3 days after application30
Yen 2026 [4]RF microneedlingFollowed the device session on one side; device alone on the otherNot described in the abstract60

The order matters for a second reason. Soltani-Arabshahi and colleagues reported in 2014 three women who developed facial granulomas after microneedling, two of whom had the same topical vitamin serum applied during the procedure, and concluded that topical products applied before microneedling can introduce immunogenic particles into the dermis [16]. Friedmann and colleagues reviewed 15 such cases in 2025 and reported that motorized pens and topical vitamin C were implicated in most of them [17].

Understanding channel closure after microneedling

Gupta and colleagues measured skin resealing in human volunteers in 2011 by electrical impedance. Unoccluded microneedle sites recovered barrier properties within two hours, while sites kept under occlusion stayed permeable for 3 to 40 hours depending on needle length, number and cross-section, and resealed rapidly once the occlusion came off [7].

Kalluri, Kolli and Banga characterized the channels in an animal model the same year. Needles 770 micrometers long made channels averaging about 153 micrometers deep and 71 micrometers wide at the surface, water-loss readings recovered within 4 to 5 hours, and dye imaging showed the pores closing by 12 hours for 370 micrometer needles and 18 hours for 770 micrometer needles [8].

Two findings show how sensitive that window is. Brogden and colleagues reported in 2012 that a topical anti-inflammatory applied daily after microneedling slowed micropore closure in human volunteers [9], which suggests that what goes on the skin afterward can change how long the channels stay open. Lee WR and colleagues reported in 2026 that water-loss readings placed RF microneedling channel closure within 12 hours in their models [10].

What the channel data mean for vesicles

No located human study has measured how deep vesicles travel through microneedle channels; the timing comes from impedance, water-loss and dye studies [7, 8]. Wang T and colleagues reported in 2023 that dye-labeled vesicles reached the deep dermis after microneedle pretreatment in an animal model [11], and Lee WR and colleagues reported that lipid nanocarriers close to small-vesicle size were distributed mainly in the channels [10].

Contact time is bounded by the channel window

Contact time for exosome material after microneedling awaits a comparative study, and the published work establishes the shape of the window: the controlled protocols applied material right after needling [2, 3], and the closure data place most of the open-channel time in the first hours [7, 8].

Occlusion is the variable that stretches the window, as Gupta and colleagues reported [7], and the granuloma reports are a reminder that open channels also let other topical products reach the dermis [16, 17]. A practice that records the interval between the needle pass and the exosome step, and whether the area was covered, builds the data that would answer the contact-time question in time.

Aftercare in the published protocols centers on barrier protection and sun

The study protocols give the clearest picture of microneedling with exosomes aftercare. Estupiñan and colleagues asked participants to stop skin care products with active ingredients, naming retinol, alpha and beta hydroxy acids, antioxidants, growth factors and hyaluronic acid, and provided an exosome cream for one side and petroleum jelly for the other, for 10 days [2].

Yusharyahya and colleagues paused the participants’ cleanser for 4 hours, sunscreen for 1 day and retinoic acid cream for 3 days after the secretome application [3]. Alster and Graham reviewed the microneedling literature in 2018 and organized their practice guide around pretreatment, technique with treatment end points, and postoperative considerations [21], a structure an aftercare sheet can follow.

The FDA’s microneedling page lists the common risks as dryness, rough skin, tightness, redness, itching, peeling, discomfort, burning, bruising, bleeding and crusting, and lists stinging or itching when cosmetic products are applied among the less common ones. The agency also flags patients who are tan or planning to be in the sun in the two weeks after the procedure [12].

  • What goes on the skin in the first hours and days, and which active products are paused, following the protocols above [2, 3]
  • Sun exposure in the two weeks that follow, as the FDA page describes [12]
  • The reactions the FDA lists as common, so patients can tell expected redness and dryness from something to report [12]
  • Whom to contact about a reaction, and the practice’s route for reporting adverse events to the FDA through MedWatch [15]

The day after microneedling with exosomes, the published measurements suggest that mechanical microneedle channels have largely closed: Gupta and colleagues recorded barrier recovery within two hours without occlusion in human volunteers [7], and Kalluri and colleagues saw pores close by 12 to 18 hours in an animal model [8]. Redness, dryness and tightness are among the effects the FDA lists as common [12], and the aftercare sheet each practice writes decides what a patient does about them.

Understanding what an FDA-authorized microneedling device covers

Aesthetic microneedling devices are Class II under 21 CFR 878.4430, classified by a June 2018 final order that followed the FDA’s March 2018 De Novo grant DEN160029 [13]. The identification describes a device using one or more needles to mechanically puncture and injure skin tissue for aesthetic use, and states that the classification does not include devices intended for transdermal delivery of topical products such as cosmetics, drugs or biologics [13].

The FDA’s microneedling page states that the agency has authorized these devices to improve the appearance of facial acne scars, facial wrinkles and abdominal scars in patients aged 22 or older. It also states that microneedling devices are not approved for delivering cosmetics, topical medications, vitamin solutions, drugs or blood products into the skin, that the risks of combining the devices with other products are not known, and that reusing a needle cartridge is unsafe even when the cartridge is cleaned [12].

The FDA’s 2020 guidance explains when a microneedling product is a device, based on whether it penetrates the living skin layers and on the claims made for it [14]. Read together, these sources describe an authorized device as authorized to needle the skin, with the exosome step standing on the material’s own lot documentation and the practice’s own description of its service.

SourceWhat it coversWhat it leaves out
21 CFR 878.4430 (2018 final order) [13]Devices that mechanically puncture skin for aesthetic use, with special controls on needle length, penetration depth and sterilityDevices intended for transdermal delivery of cosmetics, drugs or biologics
FDA microneedling devices page [12]Authorized appearance uses in patients aged 22 or older; common and less common risks; a new cartridge for each patient and sessionDelivery of any topical product; the risks of combining devices with other products, which the agency calls not known
FDA 2019 exosome safety notification [15]The agency position that there are currently no FDA-approved exosome productsAny device pairing or route

Understanding what the evidence does not yet show

The microneedling literature on exosome and secretome material is early, and its gaps are specific enough to list. Each one is also something the next study, or a careful practice record, can fill.

  • Small samples: the four controlled microneedling studies cited here enrolled 15, 28, 30 and 60 participants [1, 2, 3, 4].
  • Design limits the authors acknowledged: Estupiñan 2025 assigned treatment sides without randomization, and Yen 2026 was unblinded [2, 4].
  • No located study compares applying exosome material before, during and after the needle pass, or compares contact times.
  • No located human study has measured vesicle depth after microneedling; Wang T 2023 tracked dye-labeled vesicles in animals [11], and MISEV2023 cautions that membrane dyes may also label non-vesicular particles [19].
  • Aftercare regimens differ from study to study and have not been compared with each other [2, 3].
  • Industry ties are present: Estupiñan 2025 was supported in part by a grant from an exosome product manufacturer, and Yusharyahya 2023 had industry co-funding and declared pending patents [2, 3].
  • Gaebe and colleagues rated the certainty of the facial vesicle evidence as low or very low in a 2026 systematic review [5], and Stack and colleagues noted heterogeneity and nonstandardized protocols in their 2026 meta-analysis [6].
  • Materials differ by source, isolation and concentration, so a result for one product may not transfer to another [6, 19].

Gaebe and colleagues also reported that most of the 16 studies they reviewed found improvement in at least one skin-quality outcome and that no serious adverse events were reported [5]. The reports of harm with exosome material that Park KY described in 2025 followed intradermal injection in a nonclinical setting, a route outside surface application [18].

Documenting each exosome lot in the practice file

A file that records the same fields the published studies report lets a practice compare its own experience with the literature and answer an investigator’s or a regulator’s questions from one place. ExaVeyra exosome material ships frozen from the manufacturing facility, every vial carries its lot number, and a certificate of analysis reporting serological testing is generated for every lot and available on request with the characterization panel and cold-chain records, which covers the first part of that file.

  • The lot number, expiry, certificate of analysis and characterization panel, mapped where possible to the MISEV2023 headings for size, concentration, marker proteins and morphology [19]
  • The cold-chain record from receipt to use, the diluent, and the time between thawing or reconstitution and application, since Görgens and colleagues reported in 2022 that phosphate-buffered saline used as a diluent severely reduced vesicle recovery within minutes [20]
  • The device by model and its FDA authorization number, the needle depth, and the cartridge lot, with a new cartridge for each patient and session [12]
  • The interval from the needle pass to the exosome step, and whether the area was covered afterward
  • The aftercare sheet version given to the patient
  • Any reaction, recorded with the lot number and reported to the FDA through MedWatch [15]

Questions patients can bring to the appointment

  • Which microneedling device will be used, and is it FDA-authorized for the area being needled?
  • Will a new needle cartridge be opened for this session, as the FDA advises?
  • Which exosome product will be applied, and may I see the certificate of analysis for its lot?
  • What should I put on my skin, and avoid, in the days after, and when should I call?

Microneedling with exosome material is an active research area: Stack and colleagues identified nine ongoing registered trials of exosome products in aesthetic medicine [6], and Yen and colleagues added a 60-person randomized split-face study in 2026 [4]. Studies like these can sharpen the answers on timing and aftercare. ExaVeyra supplies exosome material to licensed practitioners with the lot documentation each session file needs. Anyone can ask the scientific team a question or apply without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing. Patients can ask their provider for the certificate of analysis for the lot used in their session, and practices ready to start can apply today or send the scientific team a question.

Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

References

  1. 1.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face comparative study over 12 weeks; three microneedling sessions three weeks apart with follow-up six weeks after the last; exosome-containing solution on one side and saline on the other (Korea); n = 28. Carries in this article: the saline-controlled microneedling comparison, with higher Global Aesthetic Improvement Scale scores and instrument gains in wrinkles, elasticity, hydration and pigmentation on the exosome side. Disclosure: no COI statement in the PubMed record.
  2. 2.Estupiñan B, Ly K, Goldberg DJ. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face, Non-Inferiority Trial. J Cosmet Dermatol. 2025;24(5):e70208. PMID 40414798. PMC12104007. doi:10.1111/jocd.70208Investigator-blinded, non-randomized, split-face, non-inferiority trial; three RF microneedling sessions at four-week intervals with topical exosomes on one half of the face and PRP on the other (USA); n = 15 enrolled, 14 completed. Carries in this article: the full text states the materials were applied immediately after the device session, that participants discontinued skin care products with active ingredients, and that the exosome side received a post-procedure exosome cream for 10 days while the PRP side received petroleum jelly; the authors list the small sample and non-randomization of treatment sides as limitations. Disclosure: supported in part by a research grant from an exosome product manufacturer to the investigators’ practice.
  3. 3.Yusharyahya SN, Japranata VV, Sitohang IBS, Legiawati L, Novianto E, Suseno LS, et al. A Comparative Study on Adipose-Derived Mesenchymal Stem Cells Secretome Delivery Using Microneedling and Fractional CO2 Laser for Facial Skin Rejuvenation. Clin Cosmet Investig Dermatol. 2023;16:387-395. PMID 36798539. PMC9926994. doi:10.2147/CCID.S401839Single-blind, randomized split-face trial comparing microneedling with fractional CO2 laser before a secretome application; Indonesian women aged 35 to 59; n = 30. Carries in this article: the full text describes microneedling to a depth of 150 micrometers with diffuse erythema as the endpoint, secretome applied afterward, and a pause after application of 4 hours for cleanser, 1 day for sunscreen and 3 days for retinoic acid cream. Disclosure: funded by a government matching fund program with a pharmaceutical company; two authors declared pending patents.
  4. 4.Yen C, Huang H, Lin C. Radiofrequency Microneedling Combined With Topical Extracellular Vesicle Preparation for Facial Rejuvenation: A Randomized Split-Face Controlled Study. J Craniofac Surg. 2026. Published online ahead of print. PMID 42635327. doi:10.1097/SCS.0000000000013266Randomized, unblinded split-face study over 12 weeks; one side received RF microneedling followed by a topical extracellular vesicle preparation, the other RF microneedling alone; n = 60. Carries in this article: the order of steps (vesicle preparation after the device session), the sample size, and the unblinded design the authors say requires cautious interpretation. Disclosure: the authors report no conflicts of interest.
  5. 5.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment; 16 studies, 503 participants. Carries in this article: the certainty rating for facial vesicle studies; most studies reported improvement in at least one outcome and no serious adverse events, risk of bias was moderate to critical for most effectiveness outcomes, and GRADE certainty was low or very low. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
  6. 6.Stack ER, Spongberg C, Braud SC, Stanton WN, Elway M. Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials. Aesthet Surg J. 2026;46(12 Suppl 2):S13-S25. PMID 41800726. doi:10.1093/asj/sjaf178Systematic review and random-effects meta-analysis; 39 human studies (search of 2 February 2025), with nine ongoing registered trials identified. Carries in this article: the heterogeneity and nonstandardized protocols the authors say limit generalizability, and the nine ongoing registered trials. Disclosure: published in a journal supplement on exosomes; the PubMed record carries no funding or COI statement.
  7. 7.Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release. 2011;154(2):148-55. PMID 21640148. PMC3164267. doi:10.1016/j.jconrel.2011.05.021Human in vivo study using electrical impedance spectroscopy across microneedle geometries, with and without occlusion. Carries in this article: unoccluded sites recovered barrier properties within 2 hours, occluded sites resealed over 3 to 40 hours depending on microneedle geometry (length, number and cross-sectional area), and the barrier resealed rapidly once occlusion was removed. Disclosure: academic authors (Georgia Institute of Technology); no COI statement in the PubMed record.
  8. 8.Kalluri H, Kolli CS, Banga AK. Characterization of microchannels created by metal microneedles: formation and closure. AAPS J. 2011;13(3):473-81. PMID 21732220. PMC3160154. doi:10.1208/s12248-011-9288-3Preclinical study in a hairless rat model with a handheld roller carrying 370 and 770 micrometer metal needles. Carries in this article: 770 micrometer needles made channels averaging about 153 micrometers deep and 71 micrometers wide at the surface; water-loss measurements recovered in 4 to 5 hours while calcein imaging showed pores closing by 12 hours (370 micrometers) and 18 hours (770 micrometers), with occlusion delaying closure. Disclosure: academic authors (Mercer University); no COI statement in the PubMed record.
  9. 9.Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Diclofenac delays micropore closure following microneedle treatment in human subjects. J Control Release. 2012;163(2):220-9. PMID 22929967. PMC3725617. doi:10.1016/j.jconrel.2012.08.015Human mechanistic proof-of-concept study measuring micropore closure by impedance spectroscopy after one microneedle session, with daily topical diclofenac sodium against placebo. Carries in this article: what was applied to the skin afterward slowed micropore healing, and the authors proposed subclinical inflammation as part of closure. Disclosure: one author was a significant shareholder in and chief scientific officer of a transdermal formulation company.
  10. 10.Lee WR, Alalaiwe A, Tsai MT, Hu S, Chang FH, Chien MY, et al. Fractional microporation-guided delivery of nanoencapsulated drugs for enhanced cutaneous and follicular absorption: a comparison of ablative laser and radiofrequency microneedling. Drug Deliv Transl Res. 2026;16(1):248-267. PMID 40439860. doi:10.1007/s13346-025-01885-xPreclinical study (porcine skin permeation plus a mouse model) comparing fractional Er:YAG laser and RF microneedling. Carries in this article: transepidermal water loss indicating RF microneedling channel closure within 12 hours, and lipid nanocarriers of 76 to 81 nanometers, close to small-vesicle size, that were distributed primarily into the microchannels. Disclosure: the authors declared no competing interests.
  11. 11.Wang T, Gao H, Wang D, Zhang C, Hu K, Zhang H, et al. Stem cell-derived exosomes in the treatment of melasma and its percutaneous penetration. Lasers Surg Med. 2023;55(2):178-189. PMID 36573453. doi:10.1002/lsm.23628Two-part study including an animal penetration model with PKH67 dye-labeled umbilical cord MSC exosomes after microneedles, a 1565 nm non-ablative fractional laser or a plasma device (China). Carries in this article: the authors reported that labeled vesicles reached the deep dermis after microneedle pretreatment in animals, the closest located vesicle-tracking data for microneedling; MISEV2023 cautions that membrane dyes may also label non-vesicular particles. Disclosure: no COI statement in the PubMed record; registered as NCT06221787.
  12. 12.U.S. Food and Drug Administration. Microneedling Devices. Content current as of 10/15/2025; verified 9 November 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devicesAgency device information page (CDRH). Carries in this article: the authorized appearance uses in patients aged 22 years or older; the common and less common risks the agency lists, including stinging or itching when cosmetic products are applied; that devices are not approved for delivery of cosmetics, topical medications, vitamin solutions, drugs or blood products into the skin; that the risks of combining the devices with other products are not known; the caution for patients who are tan or planning to be in the sun in the two weeks after; and a new cartridge for each patient and each session.
  13. 13.U.S. Food and Drug Administration. 21 CFR 878.4430, Microneedling device for aesthetic use (Class II, special controls). Classified by final order, 83 FR 26575, June 8, 2018, following De Novo DEN160029 (decision date March 1, 2018). Text verified on eCFR 9 November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-878/subpart-E/section-878.4430 and https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN160029Federal regulation, classification order and De Novo record (CDRH), product code QAI. Carries in this article: the identification reads a device using one or more needles to mechanically puncture and injure skin tissue for aesthetic use and excludes devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biologics; special controls cover needle length, penetration depth, sterility and cleaning.
  14. 14.U.S. Food and Drug Administration. Regulatory Considerations for Microneedling Products: Guidance for Industry and Food and Drug Administration Staff. November 2020 (content current as of 11/09/2020; verified 9 November 2026). Docket FDA-2017-D-4792. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-microneedling-productsFinal CDRH guidance. Carries in this article: how the agency decides whether a microneedling product is a device, by penetration into living skin layers and by the claims made for it.
  15. 15.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the statement that there are currently no FDA-approved exosome products and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, and the MedWatch route for adverse event reports.
  16. 16.Soltani-Arabshahi R, Wong JW, Duffy KL, Powell DL. Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation. JAMA Dermatol. 2014;150(1):68-72. PMID 24258303. doi:10.1001/jamadermatol.2013.6955Case series of three women with facial granulomas after microneedling (USA); n = 3; an erratum is linked to the record. Carries in this article: two of the three had the same topical vitamin serum applied during microneedling, biopsies showed foreign body-type granulomas, and the authors concluded that application of topical products prior to microneedling can introduce immunogenic particles into the dermis.
  17. 17.Friedmann DP, Mehta E, Verma KK, Harris R. Granulomatous Reactions From Microneedling: A Systematic Review of the Literature. Dermatol Surg. 2025;51(3):263-266. PMID 39584690. doi:10.1097/DSS.0000000000004450Systematic review of four databases; 13 studies describing 15 patients aged 26 to 74. Carries in this article: motorized pen use and topical vitamin C were implicated in a majority of cases, patch testing was rarely performed, and the authors described the reactions as rare and possibly treatment-resistant. Disclosure: no COI statement in the PubMed record.
  18. 18.Park KY. Adverse Reactions Following Intradermal Injection of Exosome-Based Formulations: A Case Series. J Cosmet Dermatol. 2025;24(10):e70520. PMID 41097876. PMC12528963. doi:10.1111/jocd.70520Case series; adult women after intradermal injection of exosome-containing cosmetic products in a nonclinical setting (South Korea); n = 4. Carries in this article: persistent erythema, nodules, granulomatous inflammation and scarring reported after injection, a route outside surface application. Disclosure: the author declared no conflicts of interest.
  19. 19.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline. Carries in this article: the headings a certificate of analysis should map to (separation from non-vesicular particles, size, concentration, marker proteins and morphology) and the caution that membrane dyes may complex with any lipids, including those of non-vesicular extracellular particles. Disclosure: many consortium authors list EV company affiliations, declared in the article.
  20. 20.Görgens A, Corso G, Hagey DW, Jawad Wiklander R, Gustafsson MO, Felldin U, et al. Identification of storage conditions stabilizing extracellular vesicles preparations. J Extracell Vesicles. 2022;11(6):e12238. PMID 35716060. PMC9206228. doi:10.1002/jev2.12238In vitro stability study up to 2 years across buffers and temperatures. Carries in this article: phosphate-buffered saline reduced vesicle recovery within days in storage and severely within minutes as a diluent, while buffer with human albumin and trehalose preserved vesicles at minus 80 degrees and across freeze-thaw cycles. Disclosure: several authors list affiliation with an EV therapeutics company.
  21. 21.Alster TS, Graham PM. Microneedling: A Review and Practical Guide. Dermatol Surg. 2018;44(3):397-404. PMID 28796657. doi:10.1097/DSS.0000000000001248Narrative literature review with a practice guide drawn from the publications and the authors’ experience. Carries in this article: the structure of a microneedling session (preparation before the session, technique and end points, postoperative considerations) that a practice file can follow. Disclosure: no COI statement in the PubMed record.

Ask your practitioner how their exosomes are tested

Lab analysis shows what is in a lot: particle counts, vesicle markers, sterility and how the material was stored. A practice that sources carefully can answer these questions from its supplier’s records.

Frequently Asked Questions

Should exosomes go on before or after microneedling?
The order is the practitioner’s decision, and the published exosome studies applied the material after the needle pass. Estupiñan and colleagues reported in 2025 that exosomes were applied immediately after each RF microneedling session [2], and Yusharyahya and colleagues described in 2023 a secretome application after needling to diffuse erythema [3]. Soltani-Arabshahi and colleagues concluded in 2014 that topical products applied before microneedling can introduce immunogenic particles into the dermis [16].
What do exosomes do after microneedling?
Park GH and colleagues reported in a 2023 randomized split-face study of 28 participants that the side receiving an exosome-containing solution with microneedling scored higher on the Global Aesthetic Improvement Scale than the saline side, with instrument gains in wrinkles, elasticity, hydration and pigmentation [1]. Gaebe and colleagues rated the certainty of the facial vesicle evidence as low or very low in a 2026 systematic review [5].
How long do microneedling channels stay open for exosomes?
Gupta and colleagues reported in 2011 that unoccluded microneedle sites in human volunteers recovered barrier properties within two hours, while occluded sites stayed permeable for 3 to 40 hours [7]. Kalluri and colleagues reported pore closure by 12 to 18 hours in an animal model, depending on needle length [8], and no located human study has measured how deep vesicles travel through the channels.
What is the aftercare for microneedling with exosomes?
Aftercare is set by each practice, and the published protocols show two examples. Estupiñan and colleagues reported in 2025 that participants stopped active skin care products and used an exosome cream on one side and petroleum jelly on the other for 10 days [2], and Yusharyahya and colleagues paused cleanser for 4 hours, sunscreen for 1 day and retinoic acid cream for 3 days [3]. The FDA’s microneedling page flags sun exposure in the two weeks after the procedure [12].
What should I expect the day after microneedling with exosomes?
The FDA’s microneedling page lists dryness, rough skin, tightness, redness, itching, peeling and crusting among the common risks of microneedling, and stinging or itching when cosmetic products are applied among the less common ones [12]. Gupta and colleagues reported in 2011 that unoccluded microneedle sites recovered barrier properties within two hours [7], so by the next day the channels have largely closed in those measurements; questions about a reaction belong with the treating provider.
What are the best exosomes after microneedling?
No located study compares exosome products head to head after microneedling, and Stack and colleagues noted heterogeneity and nonstandardized protocols across the human studies they pooled in 2026 [6]. The comparison a practice can make is on documentation: a lot-specific certificate of analysis and characterization panel mapped to the MISEV2023 headings [19], an unbroken cold-chain record, and labeling that states how and where the material was manufactured.
Is a microneedling device FDA-cleared to deliver exosomes?
The FDA identification at 21 CFR 878.4430 covers devices that mechanically puncture skin for aesthetic use and excludes devices intended for transdermal delivery of topical products such as cosmetics, drugs or biologics [13]. The FDA’s microneedling page states the devices are not approved for delivering topical products into the skin [12], and the agency stated in 2019 that there are currently no FDA-approved exosome products [15].
What should a practice document for each exosome lot?
The lot number, expiry, certificate of analysis and characterization panel, the cold-chain record, the diluent and the time from preparation to application, the device and cartridge, and the interval from needling to application. Görgens and colleagues reported in 2022 that phosphate-buffered saline used as a diluent severely reduced vesicle recovery within minutes [20], and the FDA routes adverse event reports through MedWatch [15].

ExaBlog Weekly for licensed practices

One email a week for licensed practices: new ExaBlog research reviews, practice guides and regulatory updates, each article citing its sources.

We write in English unless you check this box.

No spam. Unsubscribe any time.